【藥品性質提示】 根據 2019 AGS Beers Criteria，本藥品為【潛在不適當用藥 (PIM)】，不建議用於有骨折風險之老年人。

Depression, Melancholia

Venlafaxine hydrochloride is an antidepressant agent that potentiates the neurotransmitter activity in the central nervous system (CNS). It also inhibits neuronal serotonin activity, and norepinephrine and dopamine re-uptake.

Bioavailability: ∼45%; Vd: 7.5±3.7 L/kg; Protein binding: 27% ∼30%; Metabolism: Hepatic via CYP2D6 to active metabolite, O-desmethylvenlafaxine (ODV); and other metabolites; Elimination Half Life: venlafaxine: 3-7 hours; ODV: 9-13 hours; prolonged with cirrhosis (venlafaxine: ~30%, ODV: ~60%) and with dialysis (venlafaxine: ~180%, ODV: ~142%)

concomitant use of monoamine oxidase inhibitors (MAOI); risk of potentially life-threatening serotonin syndrome; hypersensitivity to venlafaxine or any other component of the product

C [FDA]

Enters breast milk/not recommended

common: Hypertension, sweating symptom, weight loss, constipation, loss of appetite, nausea xerostomia, asthenia, dizziness, dream disorder, headache, insomnia, somnolence, tremor, blurred vision, feeling nervous, abnormal ejaculation , impotence , orgasm disorder

Major depressive disorder: outpatients, 75 mg/day ORALLY (2-3 divided doses); may increase dosage by 75 mg/day every 4 days to a max dose of 225 mg/day. Venlafaxine should be taken with food.

mild to moderate renal impairment: decrease usual dose by 25 to 50%; hemodialysis: decrease usual dose by 50%

mild to moderate hepatic impairment: decrease usual dose by 50% or more.